Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported third-quarter 2020 financial results and provided updates on its pivotal Phase 3 clinical trials for vonoprazan. The company expects to complete enrollment in the PHALCON-EE trial by year-end 2020 and in the PHALCON-HP trial by Q1 2021. Top-line results are anticipated in mid-2021. The net loss for Q3 2020 was $34.1 million, down from $68.1 million in Q3 2019. Cash and equivalents stood at $226.4 million as of September 30, 2020. Phathom is enhancing its team with seasoned biopharmaceutical leaders in preparation for vonoprazan’s potential launch.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 3:30 p.m. ET. The management team will engage in one-on-one meetings throughout the virtual conference, which runs from September 14-18, 2020. Phathom focuses on developing novel treatments for gastrointestinal diseases, including a late-stage development drug, vonoprazan, aimed at treating acid-related disorders. Recorded sessions will be available for 60 days post-event.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2020 results, highlighting a net loss of $21.1 million, significantly reduced from $87.8 million in Q2 2019. This improvement was attributed to lower non-cash charges, which dropped from $57.5 million to $0.8 million. Research and development expenses surged to $14.9 million, reflecting increased clinical costs and staffing. Cash reserves stood at $247.3 million. The company resumed patient enrollment in its Phase 3 trials for vonoprazan, with topline data expected in 2021. Todd Branning was appointed CFO, enhancing the leadership team.
Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Todd Branning as Chief Financial Officer, transitioning from Interim CFO David Socks, who will remain a strategic advisor and Board member. Branning brings over 25 years of experience in finance from companies like Amneal Pharmaceuticals and Teva Pharmaceuticals, enhancing Phathom's leadership amid the potential commercialization of vonoprazan. This oral potassium-competitive acid blocker has received FDA's Fast Track status for treating H. pylori infection, supporting its promising market position.
Phathom Pharmaceuticals (Nasdaq: PHAT) has restarted patient enrollment in its Phase 3 clinical trials, PHALCON-EE and PHALCON-HP, following a temporary pause due to the COVID-19 pandemic. The trials focus on evaluating the efficacy of vonoprazan, a new treatment for gastrointestinal diseases. Phathom expects to provide top-line data in 2021. The FDA has designated vonoprazan as a qualified infectious disease product, enhancing its development prospects. The trials will assess safety and effectiveness for conditions like erosive esophagitis and H. pylori infection.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced key presentations at three virtual investor conferences in June 2020. CEO Terrie Curran and COO Azmi Nabulsi will represent the company at:
- Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:30 PM EDT.
- Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 2:10 PM EDT.
- BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:00 PM EDT.
Executive management will also engage in one-on-one meetings. For live webcasts, visit their website.